Compare Bristol-Myers Squibb Co (BMY) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $58.62 (market cap $116.30B), while Consumer Discretionary Select Sector SPDR Fund trades at $116.91. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Consumer Discretionary Select Sector SPDR Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Consumer Discretionary Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BMY | XLY | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $124.52 |
52-Week Low | $42.60 | $105.64 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLY trades at $116.04, down 1.02% today amid a bearish technical signal with selling pressure outweighing buys 12 to 4. Analyst consensus is unanimously bullish with a 100% buy rating. Recent news highlights consumer discretionary as a potential sleeper opportunity for Q3 2026, though inflation and weak consumer sentiment pose headwinds. The stock shows neutral oscillators but bearish moving averages, with support at $114 and resistance at $118.
The outlook for XLY is cautiously optimistic given strong analyst support, but risks include persistent inflation eroding discretionary spending and technical weakness. Investment opportunity hinges on a consumer spending rebound, while key risks are macroeconomic pressures and sector underperformance. The dividend scheduled for June 2026 offers minor income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
